Eleven Biotherapeutics (EBIO) Is Weak On High Volume Today

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer.

Trade-Ideas LLC identified Eleven Biotherapeutics ( EBIO) as a weak on high relative volume candidate. In addition to specific proprietary factors, Trade-Ideas identified Eleven Biotherapeutics as such a stock due to the following factors:

  • EBIO has an average dollar-volume (as measured by average daily share volume multiplied by share price) of $5.8 million.
  • EBIO has traded 226,654 shares today.
  • EBIO is trading at 13.53 times the normal volume for the stock at this time of day.
  • EBIO is trading at a new low 7.10% below yesterday's close.

'Weak on High Relative Volume' stocks are worth watching because major volume moves tend to indicate underlying activity such as material stock news, analyst downgrades, insider selling, selling from 'superinvestors,' or that hedge funds and traders are piling out of a stock ahead of a catalyst. Regardless of the impetus behind the price and volume action, when a stock moves with strength and volume it can indicate the start of a new trend on which early investors can capitalize (or avoid losses by trimming weak positions). In the event of a well-timed trading opportunity, combining technical indicators with fundamental trends and a disciplined trading methodology should help you take the first steps towards investment success.

EXCLUSIVE OFFER: Get the inside scoop on opportunities in EBIO with the Ticky from Trade-Ideas. See the FREE profile for EBIO NOW at Trade-Ideas

If you liked this article you might like

ETF Outlook: Winners and Losers In a Trump Presidency

These 5 Stocks Under $10 Could Make You a Lot of Money

Eleven Biotherapeutics (EBIO) Stock Increases, Buys Viventia Bio

It May Be Dull, but That's No Reason to Be Negative

Don't Roll the Dice on Central Bank News